News - Abzena

Filter by year

Filter by topic

Abzena and evitria announce partnership to provide best in class lead candidate selection.

Abzena, a Partner Research Organization for integrated discovery to GMP solutions for biologics and bioconjugates, and evitria AG, a best-in-class transient antibody expression service provider have announced their partnership to enhance lead candidate selection for large molecules. This collaboration will leverage evitria’s world-class reputation in rapid transient production of antibodies alongside Abzena’s lead candidate design and developability expertise underpinned by a comprehensive range […] Read more

Abzena and BioXpress Therapeutics announce partnership to support the development and manufacture of biosimilars for global customers.

Abzena, a Global Partner Research Organization for integrated bench to patient solutions for biologics and bioconjugates, and BioXpress Therapeutics, a world-class leading developer of high quality, monoclonal antibody (mAb) biosimilar therapeutics have announced their partnership to support biosimilar development for third party customers. The partnership creates an integrated solution between two leading service providers with expertise in biosimilar development and GMP manufacture.  The partnership will […] Read more

Abzena appoints Patrice Dudley Aviles as Chief Human Resource Officer

Abzena, a leading Partner Research Organization (PRO) for biopharmaceutical outsourced solutions from concept to clinic and into GMP manufacturing has announced the appointment of Patrice Dudley Aviles as the Chief Human Resource Officer. With over 25 years’ experience in the Pharmaceutical industry, Patrice has previously held roles with progressively increasing scope and responsibility at Pfizer, […] Read more

Abzena announces location of new biologics GMP manufacturing site with up to 12 X 2000L bioreactors

Abzena is a Global Partner Research Organization (PRO) specializing in the integrated development and manufacture of complex biologics and bioconjugates has announced that the location of its new GMP manufacturing facility will be Sanford, North Carolina.   The significant expansion of Abzena’s capacity is driven by an increase in customer demand for commercial scale 2000L single use […] Read more

Abzena selected by Immunome to develop and manufacture antibody cocktail for Immunome’s COVID-19 Antibody Based Treatment

Exton, PA and San Diego, CA – February 3, 2021 – Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics, and Abzena, a partner research organization for integrated discovery to cGMP manufacturing solutions for biologics, today announced that Abzena was selected as Immunome’s […] Read more

Abzena announces opening of new biologics GMP manufacturing site with up to 12 X 2000L bioreactors

Abzena, a Global Partner Research Organization for integrated bench to market solutions for biologics and bioconjugates, has announced the addition of a 6th Global site that will augment cGMP manufacturing capacity for mammalian biologics. This expansion is driven by an increase in customer demand for commercial scale 2000L single use bioreactors across a wide range […] Read more

Kimball Hall promoted to President and appointed to the Abzena board

Abzena, a Global Partner Research Organization for integrated bench to bedside solutions for biologics, complex chemistry and bioconjugates, has appointed Kimball Hall, Chief Operating Officer at Abzena as President in addition to her COO role. As part of the promotion, Kimball has also been added to the Company Board. The promotion recognizes Ms. Hall’s pivotal […] Read more

Abzena upgrades GMP chemistry and conjugation suites to allow Phase III and commercial manufacturing

Abzena, a global partner research organization for integrated bench to market solutions for biologics and bioconjugates, has announced upgrades of its chemistry GMP suites. The Bristol PA site manufacturing facility upgrades allow Abzena’s ADC client projects to seamlessly progress from discovery to commercial without technology transfer. The Bristol site enhancements includes two new GMP suites, […] Read more

Abzena invests $60m into cGMP manufacturing capacity

Leading contract provider of integrated discovery, development and manufacturing services for biologics and bioconjugates, Abzena, has invested $60m into a new facility for late phase and commercial cGMP manufacturing. The new ~50,000 sqft ‘Lusk’ facility, at the company’s site in San Diego, CA, US, houses a process development laboratory and two new cGMP manufacturing cleanrooms for […] Read more

Abzena appoints Giovanni Escobar as SVP and Site Head of Bristol, Pennsylvania Operations

Cambridge, UK and San Diego, CA,  October 5,  2020 – Abzena, a leading Partner Research Organization (PRO) for biopharmaceutical outsourced solutions from concept to clinic and into GMP manufacturing has announced the appointment of Giovanni Escobar as Senior Vice President (SVP) and Site Head of its Bristol Operations. With over 27 years’ experience in the Pharmaceutical […] Read more

Interested in our services? Get In Touch